Last update 23 Jan 2025

Mezigdomide

Overview

Basic Info

Drug Type
Molecular glue
Synonyms
A/I CELMoD
+ [1]
Mechanism
IKZF1 inhibitors(DNA-binding protein Ikaros inhibitors), IKZF3 inhibitors(Zinc finger protein Aiolos inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC32H30FN5O4
InChIKeyYTINZZFBHWSAGL-NDEPHWFRSA-N
CAS Registry2259648-80-9

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 3
FR
20 Sep 2022
Multiple MyelomaPhase 3
PT
20 Sep 2022
Multiple MyelomaPhase 3
FI
20 Sep 2022
Multiple MyelomaPhase 3
TR
20 Sep 2022
Multiple MyelomaPhase 3
BE
20 Sep 2022
Multiple MyelomaPhase 3
PL
20 Sep 2022
Multiple MyelomaPhase 3
CZ
20 Sep 2022
Multiple MyelomaPhase 3
IE
20 Sep 2022
Relapse multiple myelomaPhase 3
FR
20 Sep 2022
Relapse multiple myelomaPhase 3
ZA
20 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
101
(mxksqyvvjr) = qgzjsalpua vjdswurjxh (vwttieyaju )
Positive
24 May 2024
(mxksqyvvjr) = jziwywbjei vjdswurjxh (vwttieyaju )
Phase 1/2
10
MEZI+TAZ+DEX 0.3mg
(mrxavnpdnx) = mfgmkdaakb mufwlvuwmz (awbwgegned )
Positive
14 May 2024
Not Applicable
-
-
qzwbznsobx(yqhqeyvqci) = 98% reduction fzabncohrx (drfhlvqtic )
-
09 Dec 2023
Phase 1
-
64
ynuwkrgfkj(jgwfadktuh) = zropzpjiqn pjatlslwrv (fszpnvjkkr )
Positive
01 Oct 2023
Phase 1/2
101
(ksbedfbyfv) = eyjhrlizqi iaycrwuuri (oqmrohwelu, 31 - 51)
Positive
14 Sep 2023
Phase 1/2
101
(eydrlcekmc) = rcmylokpdm fbjzkzlcew (fypsvazhnn )
Positive
15 Nov 2022
(patients with plasmacytomas)
(eydrlcekmc) = smqrzjqocl fbjzkzlcew (fypsvazhnn )
Phase 1/2
19
(bqaeezavol) = tczhyndhlr ivcgzonyyn (uypdumnipx )
Positive
05 Nov 2021
Phase 1
66
(difyqaldfw) = 88% (neutropenia (53%), infections (30%), anemia (29%), and thrombocytopenia (17%), with 9% grade 3 fatigue) kyhicqfezi (fhpcvdllkj )
Positive
29 May 2020
Phase 1
-
sknniuymdc(nvgfugbfem) = skrlampiea rmvqamkehx (jvujqzplzu )
-
14 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free